208 related articles for article (PubMed ID: 27062421)
1. Clinical outcomes of patients with hypercalcitoninemia after initial treatment for medullary thyroid cancer and postoperative serum calcitonin cutoffs for predicting structural recurrence.
Cho YY; Jang HW; Jang JY; Kim TH; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
Head Neck; 2016 Oct; 38(10):1501-8. PubMed ID: 27062421
[TBL] [Abstract][Full Text] [Related]
2. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels.
Fanget F; Demarchi MS; Maillard L; Lintis A; Decaussin M; Lifante JC
Br J Surg; 2021 Sep; 108(9):1064-1071. PubMed ID: 33899100
[TBL] [Abstract][Full Text] [Related]
3. Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer.
Kartal Baykan E; Erdoğan M
Turk J Med Sci; 2021 Apr; 51(2):650-656. PubMed ID: 33128357
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
5. Reference values of serum calcitonin with calcium stimulation tests by electrochemiluminescence immunoassay before/after total thyroidectomy in Japanese patients with thyroid diseases other than medullary thyroid carcinoma.
Kihara M; Miyauchi A; Kudo T; Hirokawa M; Miya A
Endocr J; 2016 Jul; 63(7):627-32. PubMed ID: 27097651
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Preoperative Serum Calcitonin Levels for Predicting the Recurrence of Medullary Thyroid Carcinoma.
Park H; Park SY; Park J; Choe JH; Chung MK; Woo SY; Choi JY; Kim SW; Chung JH; Kim TH
Front Endocrinol (Lausanne); 2021; 12():749973. PubMed ID: 34675884
[TBL] [Abstract][Full Text] [Related]
7. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.
Kwon H; Kim WG; Jeon MJ; Song DE; Lee YM; Sung TY; Chung KW; Yoon JH; Hong SJ; Baek JH; Lee JH; Kim TY; Kim WB; Shong YK
Endocrine; 2016 Jul; 53(1):174-81. PubMed ID: 26754662
[TBL] [Abstract][Full Text] [Related]
8. Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: a comparative analysis of calcium and pentagastrin stimulation of serum calcitonin.
Lorenz K; Elwerr M; Machens A; Abuazab M; Holzhausen HJ; Dralle H
Langenbecks Arch Surg; 2013 Mar; 398(3):403-9. PubMed ID: 23408061
[TBL] [Abstract][Full Text] [Related]
9. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.
Verbeek HH; de Groot JWB; Sluiter WJ; Muller Kobold AC; van den Heuvel ER; Plukker JT; Links TP
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD010159. PubMed ID: 32176812
[TBL] [Abstract][Full Text] [Related]
11. Baseline and stimulated calcitonin: Thresholds for the diagnosis of medullary thyroid cancer.
Fugazzola L
Ann Endocrinol (Paris); 2019 Jun; 80(3):191-192. PubMed ID: 31053250
[No Abstract] [Full Text] [Related]
12. Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer.
Allelein S; Ehlers M; Morneau C; Schwartz K; Goretzki PE; Seppel T; Feldkamp J; Krieg A; Knoefel WT; Kuebart A; Haase M; Dringenberg T; Schmid C; Schott M
Horm Metab Res; 2018 Jan; 50(1):23-28. PubMed ID: 29169190
[TBL] [Abstract][Full Text] [Related]
13. Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years.
Jung KY; Kim SM; Yoo WS; Kim BW; Lee YS; Kim KW; Lee KE; Jeong JJ; Nam KH; Lee SH; Hah JH; Chung WY; Yi KH; Park DJ; Youn YK; Sung MW; Cho BY; Park CS; Park YJ; Chang HS
Clin Endocrinol (Oxf); 2016 Apr; 84(4):587-97. PubMed ID: 26175307
[TBL] [Abstract][Full Text] [Related]
14. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.
Toledo SP; Lourenço DM; Santos MA; Tavares MR; Toledo RA; Correia-Deur JE
Clinics (Sao Paulo); 2009; 64(7):699-706. PubMed ID: 19606248
[TBL] [Abstract][Full Text] [Related]
15. Spurious hypercalcitoninemia in patients with nodular thyroid disease induced by heterophilic antibodies.
Kim JM; Chung KW; Kim SW; Choi SH; Min HS; Kim JN; Won WJ; Kim SK; Lee JI; Chung JH; Kim SW
Head Neck; 2010 Jan; 32(1):68-75. PubMed ID: 19536770
[TBL] [Abstract][Full Text] [Related]
16. Ultrasonographic Features of Medullary Thyroid Carcinoma: Do they Correlate with Pre and PostOperative Calcitonin Levels?
Cho KE; Gweon HM; Park AY; Yoo MR; Kim J; Youk JH; Park YM; Son EJ
Asian Pac J Cancer Prev; 2016; 17(7):3357-62. PubMed ID: 27509975
[TBL] [Abstract][Full Text] [Related]
17. Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer.
Andrade F; Rondeau G; Boucai L; Zeuren R; Shaha AR; Ganly I; Vaisman F; Corbo R; Tuttle M
Arch Endocrinol Metab; 2019; 63(2):137-141. PubMed ID: 30916162
[TBL] [Abstract][Full Text] [Related]
18. DNA analysis and persistent hypercalcitoninemia in medullary thyroid carcinoma.
Jeng TK; Lee CH; Wang HC; Chiu JW; Lui WY
Zhonghua Yi Xue Za Zhi (Taipei); 1993 May; 51(5):340-4. PubMed ID: 8334560
[TBL] [Abstract][Full Text] [Related]
19. Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation in a series of 2705 patients with thyroid nodules.
Giovanella L; Imperiali M; Piccardo A; Taborelli M; Verburg FA; Daurizio F; Trimboli P
Eur J Clin Invest; 2018 Jun; 48(6):e12934. PubMed ID: 29635700
[TBL] [Abstract][Full Text] [Related]
20. Negative predictive value of procalcitonin in medullary thyroid carcinoma.
Lim SK; Guéchot J; Vaubourdolle M
Ann Biol Clin (Paris); 2016; 74(2):213-8. PubMed ID: 26806393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
